Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
It has been shown that the hallucinogenic potencies of LSD, the phenylisopropylamines, such as DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) and DOI (4-iodo-2,5-dimethoxyphenylisopropylamine), and the indolealkylamines, such as DMT (dimethyltryptamine) and 5-OMe-DMT (5-methoxy-dimethyltryptamine), strongly correlate with their in vitro 5-HT2 receptor binding affinities in rat cortical homogenates. In order to ascertain if this correlation applies to human 5-HT2 receptors as well, we examined the affinities of 13 psychoactive compounds at 3H-ketanserin-labelled 5-HT2 receptors in human cortical samples. Both radioligand binding and autoradiographical procedures were used. As in rat brain, d-LSD was the most potent displacer of 3H-ketanserin specific binding with a Ki of 0.9 nM. The phenylisopropylamine DOI also displayed high affinity (Ki of 6 nM). Stereospecific interactions were found with DOB; (-) DOB had a Ki of 17 nM while (+) DOB had a Ki of 55 nM. The behaviorally active compound DOM (4-methyl-2,5-phenylisopropylamine) had an affinity of 162 nM while its behaviorally less active congener iso-DOM had an affinity of 6299 nM. The indolealkylamines 5-OMe-DMT and DMT competed with moderate affinities (207 and 462 nM, respectively). In general, Hill coefficients were significantly less than unity which is consistent with an agonist interaction with 5-HT2 receptors. MDMA, a substituted amphetamine analog was inactive with a Ki of greater than 10 microM. A strong correlation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prototypic tryptamine hallucinogen DMT (9) had a Ki of 0.5 µM [47] or 2 µM [48] against (mainly) 5HT2A/C sites labelled with [3H]-ketanserin, indicating rather low affinity in vitro.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [47]
In the citing paper
“Indeed, the strong association between hallucinogenic properties of a broad range of structural classes of molecules with 5HT2A affinity supports the use of antagonist drugs like ketanserin (7) as a treatment for drug-induced hallucinations [47].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [47]
In the citing paper
“5-MeO-DMT (15) has similar affinity at 5HT2A receptors (Ki = 200 nM), under binding conditions where LSD (1) had a Ki of only 1 nM [47], and had >100-fold selectivity for 5HT1A/B/C receptors relative to 5HT2A receptors in vitro [56].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [47]
Citations
Cites
Handbook of Psychopharmacology
(1978) · Springer eBooks · doi:10.1007/978-1-4613-4042-3 · Cited by 1,091
A practical computer-based approach to the analysis of radioligand binding experiments
McPherson, G. A. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90031-4 · Cited by 829
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
Self-citationTiteler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343 · cited 4×
“It has been recently shown that certain phenylisopropylamines such as DOB (Titeler et al. 1988) and DOI (Hoyer and Karpf 1988) have high affinity for the 5-HT1C receptor and that a significant correlation exists between hallucinogenic potency and 5-HT1C receptor binding affinity ( Titeler et al. 1988 ).”
BackgroundResultInfluentialSelf-citationGlennon, R. A., Young, R., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90464-8 · Cited by 190
Self-citationPsychotomimetic Drugs: Structure-Activity Relationships
Shulgin, A. T. (1978) · Springer eBooks · doi:10.1007/978-1-4757-0510-2_6 · Cited by 131
Shannon, M. H., Battaglia, G., Glennon, R. A., & Titeler, M. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90333-9 · Cited by 128
Self-citationLyon, R. A., Glennon, R., & Titeler, M. (1986) · Psychopharmacology · doi:10.1007/bf00178519 · Cited by 121
Self-citationLyon, R. A., Davis, K. H., & Titeler, M. (1987) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10354-4 · Cited by 106
Self-citationRasmussen, K., & Aghajanian, G. K. (1986) · Brain Research · doi:10.1016/0006-8993(86)91090-5 · Cited by 103
Cited by
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Structure-based discovery of nonhallucinogenic psychedelic analogs
Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., et al. (2022) · Science · doi:10.1126/science.abl8615 · Cited by 312
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“Indoleamine and phenylalkylamine hallucinogens bind to 5-HT2 sites with moderate to high affinity (Shannon et al., 1984; Lyon et al., 1988; Sadzot et al., 1989; McKenna et al., 1990).”
BackgroundInfluentialMolecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. L., Meisel, A., & Carvalho, F. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 290
Knight, A., Misra, A., Quirk, K., Benwell, K., Revell, D., Kennett, G., & Bickerdike, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-004-0951-4 · Cited by 242
The behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 225
Canal, C. E., & Morgan, D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1333 · Cited by 221
Stahl, S. M. (2016) · CNS Spectrums · doi:10.1017/s1092852916000407 · Cited by 221
Serotonergic basis of antipsychotic drug effects in schizophrenia
Lieberman, J. A., Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols, D. E., & Kraus, J. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00187-5 · Cited by 206
Millière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Parkinson’s Disease Psychosis: Presentation, Diagnosis and Management
Schneider, R. B., Iourinets, J., & Richard, I. H. (2017) · Neurodegenerative Disease Management · doi:10.2217/nmt-2017-0028 · Cited by 177
Brouwer, A., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 143
Shen, H.-W., Jiang, X.-L., C. Winter, J., & Yu, A.-M. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233495 · Cited by 170
Bonson, K. R., Buckholtz, J. W., & Murphy, D. L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00145-4 · Cited by 170
D’Amico, J. M., Condliffe, E. G., Martins, K. J. B., Bennett, D. J., & Gorassini, M. A. (2014) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2014.00036 · Cited by 176
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats
Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., Eckler, J. R., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.12.015 · Cited by 145
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140
“This pattern of neurotransmitter binding affinity is similar to that of structurally similar psychedelic tryptamines (e.g., N,N-dimethyltryptamine, 5-methoxydiisopropyltryptamine; Fantegrossi et al., 2006; Rabin et al., 2002; Sadzot et al., 1989; Winter, 2009), and somewhat different from tryptamines with stronger aff…”
Adverse consequences of lysergic acid diethylamide
ABRAHAM, H. D., & ALDRIDGE, A. M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02018.x · Cited by 140
Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review
Ken Gillman, P. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2009.01575.x · Cited by 133
The human 5-HT2 receptor is encoded by a multiple intron—exon gene
Chen, K., Yang, W., Grimsby, J. S., & Shih, J. C. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90005-v · Cited by 133
Fantegrossi, W. E., Ullrich, T., Rice, K. C., Woods, J. H., & Winger, G. D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1021-6 · Cited by 132
Fantegrossi, W. E., Woods, J. H., & Winger, G. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200403000-00007 · Cited by 101
Vasoconstriction in bovine vasculature induced by the tall fescue alkaloid lysergamide2
Oliver, J. W., Abney, L. K., Strickland, J. R., & Linnabary, R. D. (1993) · Journal of Animal Science · doi:10.2527/1993.71102708x · Cited by 96
Physiological Manifestations of Endophyte Toxicosis in Ruminant and Laboratory Species
Oliver, J. W. (1997) · Springer eBooks · doi:10.1007/978-1-4899-0271-9_56 · Cited by 94
Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder
Murnane, K. S. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000459 · Cited by 97
Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives
Scorza, M. C., Carrau, C., Silveira, R., Zapata-Torres, G., Cassels, B. K., & Reyes-Parada, M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00405-x · Cited by 90
Blessing, W. W., & Seaman, B. W. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00810-2 · Cited by 93
NBOMes–Highly Potent and Toxic Alternatives of LSD
Zawilska, J. B., Kacela, M., & Adamowicz, P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00078 · Cited by 88
Bonson, K. R., & Murphy, D. L. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00102-7 · Cited by 76
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
Halberstadt, A. L., & Geyer, M. A. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1718-x · Cited by 75
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats
Fantegrossi, W. E., Harrington, A. W., Eckler, J. R., Arshad, S., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0009-4 · Cited by 77
Fantegrossi, W. E., Reissig, C. J., KATZ, E., Yarosh, H. L., Rice, K. C., & WINTER, J. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.09.007 · Cited by 78
Bull, E., Hutson, P. H., & Fone, K. C. F. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.08.004 · Cited by 71
Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome
Stahl, S. M. (2016) · CNS Spectrums · doi:10.1017/s1092852916000602 · Cited by 67
Fantegrossi, W. E., Winger, G. D., Woods, J. H., Woolverton, W. L., & Coop, A. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.07.014 · Cited by 66
Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease
Meltzer, H. Y., Kennedy, J., Dai, J., Parsa, M., & Riley, D. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00060-d · Cited by 60
5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens
Rabin, R. A., Regina, M. J., Doat, M., & Winter, J. C. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00720-1 · Cited by 58
Characterization of the human 5-HT2A receptor gene promoter
Zhu, Q., Chen, K., & Shih, J. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-07-04885.1995 · Cited by 60
Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA
Hasler, F., Studerus, E., Lindner, K., Ludewig, S., & Vollenweider, F. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108094650 · Cited by 52
Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment
van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L., Bosker, W. M., Bakker, K., & Ramaekers, J. G. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.80 · Cited by 55
Halberstadt, A. L., Powell, S. B., & Geyer, M. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.014 · Cited by 57
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 47
Mittman, S. M., & Geyer, M. A. (1991) · Psychopharmacology · doi:10.1007/bf02316866 · Cited by 55
Sakloth, F., Leggett, E., Moerke, M. J., Townsend, E. A., Banks, M. L., & Negus, S. S. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000253 · Cited by 50
Halberstadt, A. L., Buell, M. R., Masten, V. L., Risbrough, V. B., & Geyer, M. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1247-z · Cited by 45
Bioactive Alkaloids of Hallucinogenic Mushrooms
Wieczorek, P. P., Witkowska, D., Jasicka-Misiak, І., Poliwoda, A., Oterman, M., & Zielińska, K. (2015) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63462-7.00005-1 · Cited by 52
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
“5-MeO-DMT (15) has similar affinity at 5HT2A receptors (Ki = 200 nM), under binding conditions where LSD (1) had a Ki of only 1 nM [47], and had >100-fold selectivity for 5HT1A/B/C receptors relative to 5HT2A receptors in vitro [56].”
BackgroundWallis, C. J., & Lal, H. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00024-4 · Cited by 43
Basselin, M., Chang, L., Seemann, R., Bell, J. M., & Rapoport, S. I. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300611 · Cited by 47
The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA)
Freudenmann, R. W., & Spitzer, M. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00007.x · Cited by 42
Psychosis in Parkinson’s disease: ‘between a rock and a hard place’
Henderson, M. J., & Mellers, J. D. C. (2000) · International Review of Psychiatry · doi:10.1080/09540260020002541 · Cited by 43
Gatch, M. B., Rutledge, M. A., Carbonaro, T., & Forster, M. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1501-z · Cited by 38
Powell, A., Ireland, C., & Lewis, S. J. G. (2020) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.19110316 · Cited by 45
Goodwin, A., Pynnonen, D. M., & Baker, L. E. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00029-7 · Cited by 40
Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice
Dougherty, J. P., & Aloyo, V. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2207-6 · Cited by 39
`Candyflipping': Synergistic discriminative effect of LSD and MDMA
Schechter, M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01473-8 · Cited by 39
Killinger, B. A., Peet, M. M., & Baker, L. E. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.014 · Cited by 42
Effects of LSD, Ritanserin, 8-OH-DPAT, and Lisuride on Classical Conditioning in the Rabbit
Welsh, S. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00436-x · Cited by 36
The renaissance in psychedelic research: What do preclinical models have to offer
Murnane, K. S. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.003 · Cited by 38
Glennon, R. A., Higgs, R., Young, R., & Issa, H. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90488-2 · Cited by 35
Self-citationVisual hallucinations after combining fluoxetine and dextromethorphan
Achamallah, N. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.10.1406b · Cited by 33
Fluorine in psychedelic phenethylamines
Trachsel, D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.413 · Cited by 34
mGlu5-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia
Wierońska, J. M., Kłeczek, N., Woźniak, M., Gruca, P., Łasoń, M., Papp, M., Brański, P., Burnat, G., & Pilc, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.03.010 · Cited by 32
In vivo pharmacology of MDMA and its enantiomers in rhesus monkeys.
Fantegrossi, W. E. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.1.1 · Cited by 30
Helsley, S., Fiorella, D. J., Rabin, R. A., & Winter, J. C. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00031-1 · Cited by 32
Acute exacerbation of body dysmorphic disorder during tryptophan depletion
Barr, L. C., Goodman, W. K., & Price, L. H. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.10.1406a · Cited by 27
Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors
Pierce, P. A., Kim, J. Y., & Peroutka, S. J. (1992) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00167563 · Cited by 25
Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia
Lee, H. S., Bastani, B., Friedman, L., Ramirez, L. F., & Meltzer, H. Y. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90258-2 · Cited by 24
Maes, M. H. J., & Meltzer, H. Y. (1996) · Psychiatry Research · doi:10.1016/s0165-1781(96)02917-4 · Cited by 22
Optimising PET approaches to measuring 5‐ HT release in human brain
Tyacke, R. J., & Nutt, D. J. (2015) · Synapse · doi:10.1002/syn.21835 · Cited by 21
Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists
Märcher-Rørsted, E., Halberstadt, A. L., Klein, A. K., Chatha, M., Jademyr, S., Jensen, A. A., & Kristensen, J. L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00129 · Cited by 22
Animal Models for Assessing Hallucinogenic Agents
Glennon, R. A. (2003) · Humana Press eBooks · doi:10.1385/0-89603-217-5:345 · Cited by 21
Self-citationFluoxetine and visual hallucinations in dementia
Omar, S. J., Robinson, D. M., Davies, H. D., Miller, T. P., & Tinklenberg, J. R. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00195-m · Cited by 21
Vorobyeva, N. S., & Kozlova, A. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927984 · Cited by 24
Young, R., & Glennon, R. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1317-2 · Cited by 20
Self-citationAbnormal behavioral responses to fenfluramine in patients with affective and personality disorders
Myers, J. E., Mieczkowski, T. A., Perel, J. M., Abbondanza, D., Cooper, T. B., & Mann, J. J. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91200-9 · Cited by 20
Freo, U., Soncrant, T. T., Holloway, H. W., & Rapoport, S. I. (1991) · Brain Research · doi:10.1016/0006-8993(91)91074-b · Cited by 21
Pharmacologic Similarities and Differences Among Hallucinogens
Waters, K. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1917 · Cited by 21
Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats
Lucot, J. B. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90335-f · Cited by 18
Bull, E., Porkess, V., Rigby, M., Hutson, P., & Fone, K. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059583 · Cited by 16
Citrome, L., Norton, J. C., Chi‐Burris, K., & Demos, G. (2017) · CNS Spectrums · doi:10.1017/s1092852917000736 · Cited by 18
Mellers, J. D. C., Quinn, N. P., & Ron, M. A. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.4.522 · Cited by 18
Murnane, K. S., Güner, O. F., Bowen, J. P., Rambacher, K. M., Moniri, N. H., Murphy, T. J., Daphney, C. M., Oppong‐Damoah, A., & Rice, K. C. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.003 · Cited by 17
The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine
Meltzer, H. Y., Maes, M. H. J., & Lee, M. A. (1993) · Psychopharmacology · doi:10.1007/bf02245013 · Cited by 16
Kolaczynska, K. E., Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794254 · Cited by 18
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
Salinsky, L. M., Merritt, C. R., Zamora, J. C., Giacomini, J. L., Anastasio, N. C., & Cunningham, K. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239159 · Cited by 16
Doat, M., Hard, R., Winter, J. C., & Rabin, R. A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.05.011 · Cited by 13
Differential Diagnosis and Psychopharmacology of Dual Disorders
Decker, K. P., & Ries, R. K. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30145-x · Cited by 18
Effects of MDMA on the Human Nervous System
McCann, U. D., & Ricaurte, G. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00015-0 · Cited by 12
Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens
Nichols, D. E. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60921-3_21 · Cited by 18
Kaur, H., Karabulut, S., Gauld, J. W., Fagot, S. A., Holloway, K. N., Shaw, H. E., & Fantegrossi, W. E. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0023 · Cited by 13
Strategies for the Development of Selective Serotonergic Agents
Glennon, R. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-080-5_4 · Cited by 9
Self-citationHarms, A., Gündisch, D., Müller, C. E., & Kovar, K.-A. (2000) · SLAS Discovery · doi:10.1177/108705710000500410 · Cited by 8
Evaluation of the neurochemical effects of methoxetamine using brain microdialysis in mice
Fuchigami, Y., Fu, X., Ikeda, R., Kawakami, S., Wada, M., Kikura‐Hanajiri, R., Kuroda, N., & Nakashima, K. (2015) · Forensic Toxicology · doi:10.1007/s11419-015-0267-8 · Cited by 8
Metadata
- Authors
- Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M.
- Affiliations
- Johns Hopkins University (US)
- Virginia Commonwealth University (US)
- Procter & Gamble (United States) (US)
- Albany Medical College (US)
- Venue
- Psychopharmacology
- Published
- 1989-08
- Volume
- 98
- Issue
- 4
- Pages
- 495-499
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2028308920
- Cited by
- 132
- References
- 19
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 1 · 2012: 3
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH40716)
- National Institute on Drug Abuse (DA00026)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- LSD, 5-HT2 receptor, serotonin receptors, ketanserin binding, DOB, digital object identifiers, DOM, DMT, stereospecific binding, MDMA, receptor binding affinity, 5-HT2 receptor antagonist, phenylisopropylamines, indolealkylamines, Hill coefficient
- MeSH terms
- Animals, Binding, Competitive, Cerebral Cortex, Hallucinations, Hallucinogens, Humans, Ketanserin, Lysergic Acid Diethylamide, Receptors, Serotonin, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.